Provided by Tiger Trade Technology Pte. Ltd.

Moderna, Inc.

143.97
+7.355.38%
Post-market: 144.700.7300+0.51%16:42 EDT
Volume:15.28M
Turnover:2.23B
Market Cap:57.48B
PE:-17.98
High:149.73
Open:137.91
Low:135.01
Close:136.62
52wk High:176.66
52wk Low:22.28
Shares:399.24M
Float Shares:368.05M
Volume Ratio:1.39
T/O Rate:4.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.0076
EPS(LYR):-7.2600
ROE:-39.00%
ROA:-13.26%
PB:8.50
PE(LYR):-19.83

Loading ...

Moderna Posts Smaller-than-expected Q2 Loss Per Share on Lower R&D Spending

Reuters
·
Jul 31

Earnings Flash (MRNA) Moderna Posts Q2 Loss $1.97 a Share, vs. FactSet Est of $2.01 Loss

MT Newswires Live
·
Jul 31

Moderna Q2 FY26 Net Loss Narrows 5% to $0.8 Billion; Revenue Rises to $145 Million

Reuters
·
Jul 31

Stock Track | Moderna Stock Plunges 5.47% in Pre-market as Q2 Revenue Misses Estimates

Stock Track
·
Jul 31

Moderna Shares Down 5.7% Premarket After Q2 Revenue Slightly Misses Estimates

THOMSON REUTERS
·
Jul 31

Movement Alert|Moderna, Inc. Falls 5.04% in Pre-Market Trading, Market Sentiment Turns Cautious on Q2 Earnings Release

Market Focus
·
Jul 31

Moderna Q2 EPS $(1.97) Beats $(2.10) Estimate, Sales $145.000M Beat $102.998M Estimate

Benzinga Earnings
·
Jul 31

Moderna Inc Q2 Shr View $-2.08, REV View $103.0 Mln

THOMSON REUTERS
·
Jul 31

Moderna: Reiterates Plan to Deliver up to 10% Revenue Growth in 2026

THOMSON REUTERS
·
Jul 31

Moderna: Expects About 55% of Its Second Half 2026 Revenue to be Recognized in the Third Quarter

THOMSON REUTERS
·
Jul 31

Moderna: in Second Half of 2026, Preparing for Potential Approval of Mflusiva in the U.S.

THOMSON REUTERS
·
Jul 31

Moderna: Anticipates Potential Approval of Moderna's 5TH Product with August 5TH Pdufa Date for Mflusiva

THOMSON REUTERS
·
Jul 31

Moderna: Mrna-1403 Did not Meet Statistical Criteria for Early Success at Phase 3 Interim Analysis, Preparing to Enroll Additional Cohort

THOMSON REUTERS
·
Jul 31

Moderna: Q2 REV $145 Mln

THOMSON REUTERS
·
Jul 31

Moderna: Expected 2026 Year-End Cash Balance to $4.7 Bln- $5.2 Bln

THOMSON REUTERS
·
Jul 31

Moderna Q2 EPS USD -1.97 VS. Ibes Estimate USD -2.08

THOMSON REUTERS
·
Jul 31

Moderna Outlook FY Capex USD 200-300 Million

THOMSON REUTERS
·
Jul 31

Corrected-Moderna Q2 Revenue USD 145 Million VS. Ibes Estimate USD 103 Million (Corrects Amount)

THOMSON REUTERS
·
Jul 31

Movement Alert|Moderna, Inc. Rises 5.03% in Regular Trading, Multiple Analyst Upgrades and Flu Vaccine Catalyst Ahead of Earnings

Market Focus
·
Jul 31

Stock Track | Moderna Soars 5.01% Intraday on Ebola Vaccine Trial Launch, Earnings Anticipation

Stock Track
·
Jul 31